ND060

ND060 is a preclinical-stage multispecific antibody candidate being developed by Numab Therapeutics for the treatment of humoral autoimmune diseases. Engineered using the company's proprietary λ-Cap™ and MATCH™ (Multispecific Antibody-based Therapeutic CHimera) technology platforms, ND060 is designed to achieve deep and selective depletion of pathogenic B lymphocytes. The molecule is intended to engage multiple effector mechanisms to provide superior efficacy over conventional monoclonal antibodies while maintaining a favorable safety and tolerability profile. It represents a potential first-in-class approach to B-cell depletion therapy in the context of autoimmune and inflammatory conditions.